CAREDX, INC. vs RadNet, Inc., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and RDNT diverge most: on net margin, CDNA reads 24.2% and RDNT reads -0.9%; on return on equity, CDNA reads 26.1% and RDNT reads -1.5%. The rest of the comparable metrics sit closer together. What RDNT's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CDNA | RDNT |
|---|---|---|
| Price | $63.64 | $70.96 |
| Market cap | $3.3B | $5.6B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 30.7 | — |
| P/B | 7.74 | 4.01 |
| P/S | 7.19 | 2.46 |
| EV/EBITDA | 25.2 | 25.6 |
| Revenue growth | +34.3% | +18.8% |
| Operating margin | 85.8% | 6.3% |
| Net margin | 24.2% | -0.9% |
| Return on equity | 26.1% | -1.5% |
| Return on assets | 20.8% | -0.5% |
| Return on invested capital | 24.6% | 2.0% |
| FCF yield | 2.7% | 1.3% |
| Debt / equity | 0.00 | 0.96 |
| Current ratio | 4.58 | 1.48 |
| Altman Z (solvency) | 6.99 | 1.81 |
| Piotroski F (quality) | 5 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.